IBRN vs. IDNA
Compare and contrast key facts about iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).
IBRN and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBRN is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Neuro Biopharma and MedTech Index. It was launched on Aug 24, 2022. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. Both IBRN and IDNA are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IBRN or IDNA.
Correlation
The correlation between IBRN and IDNA is 0.76, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
IBRN vs. IDNA - Performance Comparison
Key characteristics
IBRN:
0.16
IDNA:
0.15
IBRN:
0.37
IDNA:
0.36
IBRN:
1.04
IDNA:
1.04
IBRN:
0.20
IDNA:
0.05
IBRN:
0.42
IDNA:
0.46
IBRN:
7.98%
IDNA:
6.88%
IBRN:
21.43%
IDNA:
21.02%
IBRN:
-30.32%
IDNA:
-68.26%
IBRN:
-8.61%
IDNA:
-57.43%
Returns By Period
In the year-to-date period, IBRN achieves a 2.65% return, which is significantly higher than IDNA's 1.24% return.
IBRN
2.65%
3.74%
1.40%
0.52%
N/A
N/A
IDNA
1.24%
4.56%
-6.82%
-0.92%
-4.63%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IBRN vs. IDNA - Expense Ratio Comparison
Both IBRN and IDNA have an expense ratio of 0.47%.
Risk-Adjusted Performance
IBRN vs. IDNA — Risk-Adjusted Performance Rank
IBRN
IDNA
IBRN vs. IDNA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IBRN vs. IDNA - Dividend Comparison
IBRN's dividend yield for the trailing twelve months is around 0.39%, less than IDNA's 0.97% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 0.39% | 0.40% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 0.97% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Drawdowns
IBRN vs. IDNA - Drawdown Comparison
The maximum IBRN drawdown since its inception was -30.32%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBRN and IDNA. For additional features, visit the drawdowns tool.
Volatility
IBRN vs. IDNA - Volatility Comparison
The current volatility for iShares Neuroscience and Healthcare ETF (IBRN) is 5.11%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 6.65%. This indicates that IBRN experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.